The objective of the Pharmacology Core is to enable the projects in this Center to develop new classes of host-targeting antiviral therapeutics for the Priority viruses. The overall goal of this core is to provide the infrastructure that will enable compounds for each project to advance in pre-clinical development. This core will establish capabilities and a Center-focused collection of expertise and advisors, which are not available on the Stanford University campus or commercially. To achieve the above goals, the pharmacology core will accomplish the following specific aims, which are to provide: (i) Medicinal chemistry capabilities to produce compound series required for: characterization of lead compounds, their structure-activity-relationships, design and synthesis of pro-drugs, and analysis of drug metabolites. (ii) In vitro characterization of drug metabolism in murine and human systems. (iii) In vivo analysis of drug metabolism in conventional mice and in mice with humanized livers. (iv) In vivo analysis of drug efficacy in mice with humanized livers. (v) Biostatistical support for analysis of all data produced by the Program's projects and by the Pharmacology Core.

Public Health Relevance

In summary, we seek to develop new classes of host-targeting antiviral therapeutics that are capable of treating multiple NIAID Emerging and Re-emerging Priority Pathogen viruses, when used alone or in combination with other available agents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109662-01
Application #
8643874
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Project Start
2014-04-10
Project End
2019-03-31
Budget Start
2014-04-10
Budget End
2015-03-31
Support Year
1
Fiscal Year
2014
Total Cost
$1,095,972
Indirect Cost
$372,905
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Puschnik, Andreas S; Marceau, Caleb D; Ooi, Yaw Shin et al. (2017) A Small-Molecule Oligosaccharyltransferase Inhibitor with Pan-flaviviral Activity. Cell Rep 21:3032-3039
Xiao, Xirui; Sankaranarayanan, Karthik; Khosla, Chaitan (2017) Biosynthesis and structure-activity relationships of the lipid a family of glycolipids. Curr Opin Chem Biol 40:127-137
Sweeney, Timothy E; Khatri, Purvesh (2017) Benchmarking Sepsis Gene Expression Diagnostics Using Public Data. Crit Care Med 45:1-10
Haynes, Winston A; Vallania, Francesco; Liu, Charles et al. (2017) EMPOWERING MULTI-COHORT GENE EXPRESSION ANALYSIS TO INCREASE REPRODUCIBILITY. Pac Symp Biocomput 22:144-153
Harrigan, Matthew P; Sultan, Mohammad M; Hernández, Carlos X et al. (2017) MSMBuilder: Statistical Models for Biomolecular Dynamics. Biophys J 112:10-15
Chen, Xiaohua; Oidovsambuu, Odgerel; Liu, Ping et al. (2017) A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians. Hepatology 66:1739-1749
Liu, Bowen; Ramsundar, Bharath; Kawthekar, Prasad et al. (2017) Retrosynthetic Reaction Prediction Using Neural Sequence-to-Sequence Models. ACS Cent Sci 3:1103-1113
Mendoza, Juan L; Schneider, William M; Hoffmann, Hans-Heinrich et al. (2017) The IFN-?-IFN-?R1-IL-10R? Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity. Immunity 46:379-392
Bekerman, Elena; Neveu, Gregory; Shulla, Ana et al. (2017) Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest 127:1338-1352
Pillay, Sirika; Zou, Wei; Cheng, Fang et al. (2017) AAV serotypes have distinctive interactions with domains of the cellular receptor AAVR. J Virol :

Showing the most recent 10 out of 46 publications